Figure 1
Figure 1. D609 inhibits gp120-mediated CCL2 secretion in MDMs. Monocytes were seeded in 48-well cluster plates (5 × 105 cells/mL per well). After 7 days, culture medium was removed and replaced with 0.5 mL fresh medium. (A) MDMs were treated with different concentrations of D609 (12.5, 25, 50 μg/mL) or left untreated. At all concentrations used, this inhibitor did not affect cell viability (data not shown). After 30 minutes, some cultures were exposed to R5 gp120 (1 μg/mL). After 24 hours of culture, supernatants were harvested and frozen before CCL2 determination. Data are the means (± SD) of the results obtained with 3 different donors. (B,C) MDMs were treated with D609 (50 μg/mL) or left untreated, and then exposed to R5 gp120 as described in panel A. In panel B, the results obtained with 6 different donors, representative of 12 tested, are shown. In panel C, data are the means (± SD) of the results obtained with all the donors analyzed. *P < .05; **P < .005.

D609 inhibits gp120-mediated CCL2 secretion in MDMs. Monocytes were seeded in 48-well cluster plates (5 × 105 cells/mL per well). After 7 days, culture medium was removed and replaced with 0.5 mL fresh medium. (A) MDMs were treated with different concentrations of D609 (12.5, 25, 50 μg/mL) or left untreated. At all concentrations used, this inhibitor did not affect cell viability (data not shown). After 30 minutes, some cultures were exposed to R5 gp120 (1 μg/mL). After 24 hours of culture, supernatants were harvested and frozen before CCL2 determination. Data are the means (± SD) of the results obtained with 3 different donors. (B,C) MDMs were treated with D609 (50 μg/mL) or left untreated, and then exposed to R5 gp120 as described in panel A. In panel B, the results obtained with 6 different donors, representative of 12 tested, are shown. In panel C, data are the means (± SD) of the results obtained with all the donors analyzed. *P < .05; **P < .005.

Close Modal

or Create an Account

Close Modal
Close Modal